OncoSentia MRD test for NSCLC

Clinical evidence for ctDNA-based MRD testing continues to expand, whilst its integration into guidelines and routine cancer care progressively evolves.

Longitudinal ctDNA monitoring is creating new opportunities to investigate more personalised approaches to cancer monitoring during and after treatment.

Definitive treatment → OncoSentia MRD assessment → Consolidation therapy → Serial OncoSentia MRD monitoring → Surveillance

• ctDNA detection was associated with disease progression
  Across longitudinal samples, detectable ctDNA was associated with an approximately threefold higher risk of disease progression (HR 2.95; 95% CI 1.69–5.15). ¹
• ctDNA status during durvalumab consolidation provided prognostic information
  Detectable ctDNA 6 months into durvalumab consolidation was associated with inferior progression-free survival (HR 2.45; 95% CI 1.18–5.11). ¹
• ctDNA after completion of consolidation showed a strong association with progression risk
  Three months after completion of durvalumab, detectable ctDNA was associated with inferior progression-free survival (HR 5.37; 95% CI 1.93–14.93). ¹
• Molecular progression preceded radiological progression
  Among patients who progressed and had detectable ctDNA, molecular recurrence preceded radiological or clinical progression by a median of 7.4 months. ¹

This lead-time illustrates the potential of ctDNA monitoring to provide earlier molecular insight into emerging disease progression alongside conventional clinical and radiological surveillance.

MRD assessment provides additional molecular information on disease status, with serial ctDNA monitoring offering a longitudinal view of how molecular disease evolves over time and across clinically relevant timepoints. These insights can complement established clinical and imaging evaluations, help identify patients with detectable ctDNA who may be at increased risk of disease progression, ¹ and support the identification and consideration of patients who may be eligible for clinical trials evaluating MRD-guided management strategies.

• Designed and developed for unresectable NSCLC
  OncoSentia MRD is designed to support the molecular monitoring needs of patients diagnosed with NSCLC following definitive non-surgical treatment, including consolidation therapy and post-treatment surveillance.

• Plasma-informed personalisation without tumour tissue
  Patient sample-specific biomarker tracking is informed by plasma-derived molecular signals, without requiring prior tumour tissue sampling.

• Longitudinal assessment
  Molecular disease signals can change throughout treatment and follow-up. Longitudinal ctDNA monitoring with OncoSentia MRD tracks evolving disease status during consolidation therapy and surveillance.

• Clinically relevant molecular information
  ctDNA status offers additional insight into disease progression risk in unresectable NSCLC.¹

• Minimally invasive and repeatable
  A peripheral blood sample enables repeat testing at clinically relevant timepoints without repeated tissue sampling.

The OncoSentia MRD report provides the ctDNA status for the evaluated timepoint.

ctDNA detected

• Associated with higher risk of disease progression
• ctDNA was detected in the blood sample.
• The presence of ctDNA during or after consolidation therapy has been associated with a higher risk of disease progression for patients with unresectable NSCLC, based on data from the DART study with patients undergoing consolidation immunotherapy¹. Correlation with clinical findings and re-testing at clinically relevant intervals is recommended.

ctDNA not detected

• Associated with lower risk of disease progression
• ctDNA was not detected in the blood sample.
• The absence of ctDNA during and after consolidation therapy has been associated with a lower risk of disease progression for patients with unresectable NSCLC, based on data from the DART study with patients undergoing consolidation immunotherapy¹. Correlation with clinical findings and re-testing at clinically relevant intervals is recommended.
• A ctDNA not detected result does not rule out cancer nor eliminate the risk for disease progression.

Results are communicated directly to the healthcare provider within 2–3 weeks. Results should be interpreted alongside clinical findings, with repeat testing at clinically relevant intervals.

Sample: Two 10mL Streck tubes

Tumour tissue: Not required

Technology: Tumour-agnostic, plasma-informed hybrid capture NGS coupled with multi-modal MRD classification

Result: ctDNA detected / ctDNA not detected

Clinical application: Dynamic monitoring of MRD status with serial testing at clinically relevant timepoints during consolidation and surveillance pathways

Depending on the patient’s clinical context, OncoSentia MRD results may:

• Support patient risk stratification.
• Provide additional molecular information for multidisciplinary evaluation alongside imaging and clinical findings.
• Support longitudinal assessment of MRD status and consideration of further clinical evaluation where appropriate.
• Identify patients for clinical trials investigating MRD-guided management.

Clinical decisions should remain based on the totality of available clinical evidence and applicable treatment guidelines

1. Horndalsveen H, Haakensen VD, Madebo T, Grønberg BH, Halvorsen TO, Bjaanæs MM, Danielsen BK, Børve M, Kokkvoll S, Boda TSD, Öjlert ÅK, Helland Å. ctDNA-Based MRD Detection in Stage III NSCLC Treated With Chemoradiotherapy and Durvalumab. J Thorac Oncol. 2026 Oct;21(10):103992. doi: 10.1016/j.jtho.2026.103992. Epub 2026 Jun 23. PMID: .